Unravelling the link between SARS-CoV-2 mutation frequencies, patient comorbidities, and structural dynamics.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
14
09
2023
accepted:
23
02
2024
medline:
18
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
epublish
Résumé
Genomic surveillance is crucial for tracking emergence and spread of novel variants of pathogens, such as SARS-CoV-2, to inform public health interventions and to enforce control measures. However, in some settings especially in low- and middle- income counties, where sequencing platforms are limited, only certain patients get to be selected for sequencing surveillance. Here, we show that patients with multiple comorbidities potentially harbour SARS-CoV-2 with higher mutation rates and thus deserve more attention for genomic surveillance. The relationship between the patient comorbidities, and type of amino acid mutations was assessed. Correlation analysis showed that there was a significant tendency for mutations to occur within the ORF1a region for patients with higher number of comorbidities. Frequency analysis of the amino acid substitution within ORF1a showed that nsp3 P822L of the PLpro protease was one of the highest occurring mutations. Using molecular dynamics, we simulated that the P822L mutation in PLpro represents a system with lower Root Mean Square Deviation (RMSD) fluctuations, and consistent Radius of gyration (Rg), Solvent Accessible Surface Area (SASA) values-indicate a much stabler protein than the wildtype. The outcome of this study will help determine the relationship between the clinical status of a patient and the mutations of the infecting SARS-CoV-2 virus.
Identifiants
pubmed: 38483913
doi: 10.1371/journal.pone.0291892
pii: PONE-D-23-28307
pmc: PMC10939192
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291892Informations de copyright
Copyright: © 2024 Azzeri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Virus Evol. 2018 Jan 08;4(1):vex042
pubmed: 29340210
PLoS One. 2021 Oct 11;16(10):e0258513
pubmed: 34634066
ACS Pharmacol Transl Sci. 2023 Feb 27;6(3):334-354
pubmed: 36923110
J Open Source Softw. 2021;6(57):
pubmed: 34189396
Clin Infect Dis. 2021 Aug 2;73(3):e815-e821
pubmed: 33507235
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
J Transl Med. 2023 Feb 25;21(1):152
pubmed: 36841805
Int J Med Sci. 2022 Jan 24;19(2):402-415
pubmed: 35165525
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Virus Genes. 2021 Oct;57(5):413-425
pubmed: 34251592
Front Cell Infect Microbiol. 2022 Mar 21;12:868414
pubmed: 35386683
Saudi J Biol Sci. 2022 Jan;29(1):526-533
pubmed: 34548835
J Epidemiol Glob Health. 2020 Sep;10(3):204-208
pubmed: 32954710
Virus Evol. 2022 Aug 11;8(2):veac050
pubmed: 35996593
Nat Commun. 2021 Feb 2;12(1):743
pubmed: 33531496
Elife. 2023 Apr 04;12:
pubmed: 37014792
ACS Cent Sci. 2017 Dec 27;3(12):1311-1321
pubmed: 29296672
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
Genes (Basel). 2022 Mar 21;13(3):
pubmed: 35328105
Viruses. 2020 Jan 24;12(2):
pubmed: 31991541
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Front Genet. 2022 Apr 27;13:888025
pubmed: 35571054
Genomics. 2022 Sep;114(5):110466
pubmed: 36041637
Emerg Infect Dis. 2020 Jun;26(6):1320-1323
pubmed: 32125269
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Lancet Infect Dis. 2020 Nov;20(11):1263-1272
pubmed: 32679081
ACS Infect Dis. 2022 Mar 11;8(3):596-611
pubmed: 35199517
Front Public Health. 2022 Jun 20;10:870386
pubmed: 35795707
Immunol Rev. 2020 Jul;296(1):205-219
pubmed: 32658335
Mol Biol Evol. 2020 Aug 1;37(8):2461
pubmed: 32556291
Front Immunol. 2022 Nov 28;13:1034444
pubmed: 36518757
Int J Infect Dis. 2022 Dec;125:216-226
pubmed: 36336246